|1.||Yoshida, T: 1 article (02/2000)|
|2.||Imaoka, S: 1 article (02/2000)|
|3.||Funae, Y: 1 article (02/2000)|
|4.||Shibata, M: 1 article (02/2000)|
|5.||Numazawa, S: 1 article (02/2000)|
|1.||Cleft Palate (Palate, Cleft)
02/01/2000 - "A teratogenic compound cis-1-[-4-(p-menthane-8-yloxy)phenyl]piperadine (YM9429) selectively induces skeletal malformations characterized by cleft palate in rat fetuses. "
02/01/1995 - "YM9429 induced fetal cleft palate in vivo in CD rats when dams were orally treated during days 11-14 of pregnancy at dose of 500 mg/kg/day, but no abnormalities were detected when treated on days 15-16 (Shibata, 1993). "
08/01/1993 - "YM9429 induced cleft palate and specific skeletal variations including accessory cervical and lumbar ribs or excessive formation of the 7th lumbar vertebra by oral treatment during the organogenetic periods. "
09/01/1996 - "YM 9429 (cis-1-[4-(p-menthan-8-yloxy)phenyl]piperidine) is a hypolipidemic agent with a potent and specific teratogenicity, inducing cleft palate and skeletal variations in rats. "
08/14/1996 - "A teratogenic compound cis-1-[4-(p-menthane 8-yloxy)phenyl]piperidine (YM9429) induces cleft palate selectively in rat fetuses. "
09/01/1996 - "These results suggest that YM 9429 induced developmental abnormalities in rats by the same mechanism as the Smith-Lemli-Opitz syndrome. "
09/01/1996 - "Since cleft palate is generally observed in the Smith-Lemli-Opitz syndrome, a common syndrome of multiple congenital anomalies caused by reduced activity of 7-dehydrocholesterol delta 7-reductase (3 beta-hydroxysteroid delta 7-reductase), the final enzyme in the cholesterol biosynthetic pathway, YM 9429 was suspected of being an inhibitor of this enzyme. "
|3.||Experimental Liver Neoplasms
08/14/1996 - "The effect of YM9429 on chondrogenic differentiation was investigated using mouse embryonic carcinoma ATDC5 cells that produce chondrocyte specific extracellular matrix upon insulin stimulation. "
08/14/1996 - "Inhibition of insulin-induced chondrogenic differentiation of embryonic carcinoma cells by a teratogenic compound YM9429."